<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diagnosis of <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) with flow cytometry traditionally involves the analysis of CD55 and CD59 on RBCs and neutrophils </plain></SENT>
<SENT sid="1" pm="."><plain>However, the ability to accurately detect <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> RBCs is compromised by prior <z:mp ids='MP_0010163'>hemolysis</z:mp> and/or transfused RBCs </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) can also produce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> clones </plain></SENT>
<SENT sid="3" pm="."><plain>We recently described a multiparameter fluorescent aerolysin (FLAER)-based flow assay using CD45, CD33, and CD14 that accurately identified <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> monocyte and neutrophil clones in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>, AA, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we compared the efficiency of this WBC assay with a CD59-based assay on RBCs during a 3-year period </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> clones were detected with the FLAER assay in 63 (11.8%) of 536 samples tested, whereas <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> RBCs were detected in only 33 (6.2%), and always with a smaller clone size </plain></SENT>
<SENT sid="6" pm="."><plain>The FLAER assay on WBCs is a more sensitive and robust primary screening assay for detecting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> clones in clinical samples </plain></SENT>
</text></document>